InnoCare gets approval of clinical trial of Zurletrectinib for the treatment of pediatric patients in China
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
CARA is a data and content management platform that helps companies in regulated industries such as finance, energy, and manufacturing transform their complex business processes
Approval to dramatically change CAR-T therapies landscape
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Subscribe To Our Newsletter & Stay Updated